Kushal T Kadakia,Sanket S Dhruva,Harlan M Krumholz
Kushal T Kadakia
Correction [0.03%]
改正_spacing_错误
Cardiac Biomarkers as an Early Warning System in Transthyretin Cardiac Amyloidosis [0.03%]
transthyretin心脏淀粉样变性早期预警标志物的研究
Joshua D Mitchell,Nicole Nakamatsu,Richard K Cheng
Joshua D Mitchell
Impact of Vutrisiran on Cardiac Biomarkers in Patients With Transthyretin Amyloidosis With Cardiomyopathy From HELIOS-B [0.03%]
Vutrisiran对心脏淀粉样变性心肌病患者生物标志物影响的亚组分析：HELIOS-B试验
Mathew S Maurer,John L Berk,Thibaud Damy et al.
Mathew S Maurer et al.
Background: Before the development of disease-modifying therapies for transthyretin amyloidosis cardiomyopathy (ATTR-CM), N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) and troponin I/T were recognized as...
Randomized Controlled Trial
Journal of the American College of Cardiology. 2025 Aug 12;86(6):459-475. DOI:10.1016/j.jacc.2025.04.055 2025
Structure, Function, and Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From HELIOS-B [0.03%]
转甲状腺素蛋白淀粉样变性心肌病的结构、功能和结局：来自HELIOS-B研究的启示
Michelle M Kittleson
Michelle M Kittleson
Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy [0.03%]
Vutrisiran对转甲状腺素蛋白淀粉样变性心肌病患者心脏功能和结局的影响
Karola S Jering,Marianna Fontana,Hicham Skali et al.
Karola S Jering et al.
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM), caused by deposition of transthyretin amyloid fibrils in the heart, is associated with high morbidity and mortality. In HELIOS-B (A Study to Evaluate Vutrisiran ...
Randomized Controlled Trial
Journal of the American College of Cardiology. 2025 Aug 12;86(6):444-455. DOI:10.1016/j.jacc.2025.06.022 2025
Switching Anticoagulants and Managing Complexity in Frail Patients With Atrial Fibrillation: An Integrated Approach [0.03%]
frail患者抗凝药物转换及复杂病情管理的综合策略
Giulio Francesco Romiti,Gregory Y H Lip
Giulio Francesco Romiti
Outcomes in Older Patients After Switching to a Newer Anticoagulant or Remaining on Warfarin: The COMBINE-AF Substudy [0.03%]
SWITCH研究的COMBINE-AF子研究：老年患者换用新型抗凝药物与继续使用华法林的结局比较
Andre M Nicolau,Robert P Giugliano,Andre Zimerman et al.
Andre M Nicolau et al.
Background: Whether frail, elderly patients with atrial fibrillation (AF) on a vitamin K antagonist (VKA) should switch to a direct-acting oral anticoagulant (DOAC) was studied in the FRAIL-AF trial and remains controvers...
Randomized Controlled Trial
Journal of the American College of Cardiology. 2025 Aug 12;86(6):426-439. DOI:10.1016/j.jacc.2025.05.060 2025
Albert Y Liu,Cara N Pellegrini
Albert Y Liu